Dr Reddy's Labs to acquire Slayback Pharma OTC ophthalmic product rights

The agreement also provides Dr. Reddy's exclusive rights to the product outside the U.S. Slayback Pharma is the first company to file an ANDA for the private label equivalent for Lumify with the USFDA under Paragraph IV certification. The ANDA is currently under USFDA review and covers Brimonidine Tartrate Ophthalmic Solution 0.025% in 2.5 ml and 7.5 ml fill volumes.

"We are pleased to license this important OTC ophthalmic product for the U.S. market," says Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy's.

"This product complements Dr. Reddy's growing OTC product portfolio in the eyecare category that includes the private label versions of Pataday Once Daily Relief and Pataday Twice Daily Relief." "Slayback is proud to develop this first-to-file ANDA for Lumify, a significant OTC product in the eye redness reliever category, that continues to highlight the R&D capability of the company," said Ajay Singh, CEO and Founder of Slayback.

The value of total addressable market for this product in the U.S. is approximately $130 million for the 52 weeks period ending June 12, 2022.

Read also: Dr Reddy's Labs unveils Bortezomib for Injection in US

Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company headquartered in Hyderabad, Telangana, India. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.

Dr. Reddy's operates in markets across the globe. The company's major markets include - USA, India, Russia & CIS countries, and Europe.

Read also: Dr Reddy's Labs unveils generic version of Allegra in US